<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)
NOVITRON INTERNATIONAL, INC.
________________________________________________________________________________
(Name of Issuer)
COMMON STOCK, $.01 par value share
________________________________________________________________________________
(Title of Class of Securities)
670088103
_______________________________________________________________
(CUSIP Number)
Third Security, LLC
The Governor Tyler
1902 Downey Street
Radford, Virginia 24141
Attention: Marcus E. Smith, Esq.
Telephone No.: 540-731-3344
________________________________________________________________________________
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
Copy to:
John Owen Gwathmey, Esq.
Hunton & Williams
Riverfront Plaza, East Tower
951 East Byrd Street
Richmond, Virginia 23219
March 10, 2000
_______________________________________________________________
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [_].
Page 1 of 8 Pages
<PAGE>
- -------------------------- -----------------------
CUSIP NO. 670088103 SCHEDULE 13D Page 2 of 8 Pages
- -------------------------- -----------------------
- ------------------------------------------------------------------------------
NAMES OF REPORTING PERSONS
1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only).
Randal J. Kirk S.S. No.: ###-##-####
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
2 (a) [_]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
SOURCE OF FUNDS
4
PF
- ------------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [_]
5
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6
United States
- ------------------------------------------------------------------------------
SOLE VOTING POWER
7
NUMBER OF
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 8
OWNED BY 393,333
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
9
REPORTING
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 10
393,333
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
393,333
- ------------------------------------------------------------------------------
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
12
[_]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13
27.3%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON
14
IN
- ------------------------------------------------------------------------------
<PAGE>
- -------------------------- -----------------------
CUSIP NO. 670088103 SCHEDULE 13D Page 3 of 8 Pages
- -------------------------- -----------------------
- ------------------------------------------------------------------------------
NAMES OF REPORTING PERSONS
1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only).
Clinical Chemistry Holdings, Inc. I.R.S. Identification No.: 52-2202556
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
2 (a) [_]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
SOURCE OF FUNDS
4
WC
- ------------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [_]
5
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6
Delaware
- ------------------------------------------------------------------------------
SOLE VOTING POWER
7
NUMBER OF
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 8
OWNED BY 393,333
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
9
REPORTING
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 10
393,333
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
393,333
- ------------------------------------------------------------------------------
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
12
[_]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13
27.3%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON
14
CO
- ------------------------------------------------------------------------------
<PAGE>
This Amendment No. 1 (the "Amendment") amends and supplements the Statement
on Schedule 13D, dated November 26, 1999 and filed on December 6, 1999 (the
"Original Schedule 13D"), relating to the Common Stock, par value $.01 per share
(the "Common Stock"), of Novitron International, Inc., a Delaware corporation
(the "Issuer"). Mr. Randal J. Kirk and Clinical Chemistry Holdings, Inc., a
Delaware corporation that is controlled by Mr. Kirk ("CCH" and, together with
Mr. Kirk, the "Reporting Persons"), are filing this Amendment to update the
information in the Original Schedule 13D with respect to the beneficial
ownership of the Common Stock by the Reporting Persons.
Item 3. Source and Amount of Funds or Other Consideration.
--------------------------------------------------
Item 3 of the Original Schedule 13D is hereby amended and supplemented as
follows:
"During the period commencing February 2, 2000 and ending March 14, 2000,
CCH used approximately $84,076 of working capital to purchase 32,100 shares of
Common Stock and sold 10,000 shares of Common Stock for approximately $20,644."
Item 5. Interest in Securities of the Issuer.
-------------------------------------
Item 5(a) of the Original Schedule 13D is hereby amended to read in its
entirety as follows:
"The aggregate number and percentage of shares of Common Stock to which
this statement relates is 393,333 shares, representing 27.3% of the
1,441,925 shares outstanding as reported by the Issuer on February 8, 2000 in
the Issuer's Quarterly Report on Form 10-Q for the quarter ended December 31,
1999 (the most recent available filing by the Issuer with the Securities and
Exchange Commission). CCH beneficially owns all of the shares to which this
statement relates, and Mr. Kirk is deemed to have beneficial ownership of the
shares owned by CCH."
Item 5(c) of the Original Schedule 13D is hereby amended and supplemented
as follows:
"The following table lists all transactions in shares of Common Stock by
the Reporting Persons that were effected from December 6, 1999, the date on
which this Statement on Schedule 13D was originally filed with the Securities
and Exchange Commission, through March 14, 2000:
<TABLE>
<CAPTION>
Shares Purchased Average Price
Reporting Person Date (Sold) Per Share**
- --------------------------------------------------------------------------------------------
<S> <C> <C> <C>
CCH 2/2/00 2,400 $1.94
CCH 2/3/00 1,000 $1.94
CCH 2/4/00 1,500 $1.97
CCH 2/18/00 1,000 $3.00
CCH 2/22/00 1,000 $3.00
CCH 2/23/00 1,800 $3.00
CCH 2/28/00 2,000 $3.00
</TABLE>
Page 4 of 8 Pages
<PAGE>
<TABLE>
Shares Purchased Average Price
Reporting Person Date (Sold) Per Share**
- --------------------------------------------------------------------------------------------
<S> <C> <C> <C>
CCH 3/6/00 1,500 $3.00
CCH 3/9/00 1,500 $2.88
CCH 3/10/00 4,000 $2.75
CCH 3/13/00 7,000 $2.41
CCH 3/13/00 (10,000) $2.06
CCH 3/14/00 7,400 $2.77
</TABLE>
* Unless otherwise indicated, all transactions were effected on the Nasdaq.
** Price excludes commission."
Item 7 Material to be Filed as Exhibits.
---------------------------------
The following document is being filed as an exhibit to this Amendment
and is incorporated herein by reference:
Exhibit 7. Joint Filing Agreement.
Page 5 of 8 Pages
<PAGE>
SIGNATURE
---------
After reasonable inquiry and to the best of their knowledge and belief, the
undersigned certify that the information set forth in this statement is true,
complete and correct.
Date: March 15, 2000 /s/ Randal J. Kirk
-------------------------------
Randal J. Kirk
Date: March 15, 2000 CLINICAL CHEMISTRY HOLDINGS, INC.
By: /s/ Audrey Ho Ping Ting
-----------------------
Audrey Ho Ping Ting
President and Chief Executive Officer
Page 6 of 8 Pages
<PAGE>
EXHIBIT INDEX
-------------
Exhibit Number Exhibit
- -------------- -------
Exhibit 7. Joint Filing Agreement.
Page 7 of 8 Pages
<PAGE>
Exhibit 7
---------
JOINT FILING AGREEMENT
----------------------
In accordance with Rule 13d-1(f) promulgated under the Securities Exchange
Act of 1934, as amended, the persons names below agree to the joint filing on
behalf of each of them a Statement on Schedule 13D (including amendments
thereto) with regard to the common stock of Novitron International, Inc., and
further agree that this Joint Filing Agreement be included as an Exhibit to such
joint filings. In evidence thereof, the undersigned, being duly authorized,
hereby execute this agreement as of the 6th day of December, 1999.
Date: December 6, 1999 /s/ Randal J. Kirk
-----------------------------------------
Randal J. Kirk
Date: December 6, 1999 CLINICAL CHEMISTRY HOLDINGS, INC.
By: /s/ Audrey Ho Ping Ting
-----------------------
Audrey Ho Ping Ting
President and Chief Executive Officer
Pages 8 of 8 Pages
